TranS1

TranS1 is a United States-based medical device company focused on minimally invasive spine surgery. According to its official website, the company designs, develops, and commercializes "transformational approaches to the spine" intended to minimize the damage caused by traditional open surgical approaches. Its stated mission is captured in the trademarked phrase "Building Better Pathways™," which the company uses to describe its effort to solve unmet clinical needs and create value-based solutions for surgeons, patients, and the healthcare system. The company's flagship technology is the AxialLIF+ (Axial Lumbar Interbody Fusion) System, designed to create a safe and reproducible anterior retroperitoneal pre-sacral access route to the L5-S1 vertebral bodies. TranS1 also offers the Vectre™ Facet Fusion System, a posterior fixation solution that uses a cannulated facet screw inserted over a guidewire to reduce muscle and tissue trauma. These products reflect the company's core positioning: enabling spine surgery through less invasive pathways rather than traditional open approaches. TranS1 presents itself as a specialist in the presacral approach and AxiaLIF procedures, stating that its team includes primary experts in these techniques. The company provides surgeon resources and training opportunities, indicating a focus on procedure adoption and surgeon education. Its leadership includes Chief Executive Officer Robert L. Bundy, who is responsible for strategic vision and mission and has over 40 years of industry experience, and Chief Operating Officer Thomas A. Hoghaug. The company describes itself as operating under new ownership, suggesting a change in control at some point in its history. Wikidata identifies TranS1 as a company in Wilmington, United States. The company's official website is trans1.com. While the exact founding year and ownership structure are not specified in the available evidence, TranS1 remains an active medical device brand in the spine surgery market, with a product portfolio centered on axial and facet fusion technologies.

TranS1 is a medical device company that has designed, developed, and commercialized transformational approaches to the spine since its inception. The company states that its technologies have been used by thousands of surgeons to minimize the damage associated with traditional surgical approaches. Its history is closely tied to the development and promotion of the AxiaLIF procedure and the presacral approach to the lumbar spine. The company's foundational product, the AxialLIF+ (Axial Lumbar Interbody Fusion) System, was developed to create a safe and reproducible anterior retroperitoneal pre-sacral access route to the L5-S1 vertebral bodies. This approach represented a departure from traditional open spine surgery by accessing the spine through a small presacral corridor rather than a large posterior incision. TranS1 later added the Vectre™ Facet Fusion System, a posterior fixation device using a cannulated facet screw inserted over a guidewire, designed to reduce muscle and tissue trauma. At some point, TranS1 underwent a change in ownership. The company's website refers to "its new ownership" in the context of CEO Robert L. Bundy's leadership, indicating that the company was acquired or recapitalized. Under this new ownership, Bundy, with over 40 years of industry experience, was brought in as Chief Executive Officer to lead the company's strategic vision and mission. Thomas A. Hoghaug serves as Chief Operating Officer. TranS1 has maintained a focus on surgeon education and procedure adoption, offering training opportunities and surgeon resources through its website. The company describes its team as consisting of the world's primary experts in AxiaLIF, the presacral approach, and other minimally invasive procedures. Its stated philosophy is to solve true unmet clinical needs and create value-based solutions for surgeons, patients, and the healthcare system, operating under the trademarked banner "Building Better Pathways™." Wikidata records TranS1 as a company in Wilmington, United States. The company remains active in the medical device sector, specifically in minimally invasive spine surgery.

• TranS1 designs, develops, and commercializes transformational approaches to the spine, including the AxiaLIF+ System.

• TranS1 adds the Vectre™ Facet Fusion System to its product portfolio.

• TranS1 undergoes a change in ownership, with Robert L. Bundy appointed CEO under new ownership.

Minimally invasive spine surgery solutions that reduce tissue damage compared to traditional open approaches, marketed under the trademarked phrase "Building Better Pathways™."

• AxiaLIF+ (Axial Lumbar Interbody Fusion) System

  Designed to create a safe and reproducible anterior retroperitoneal pre-sacral access route to the L5-S1 vertebral bodies.

• Vectre™ Facet Fusion System

  Designed to offer a safe, reproducible posterior fixation by offering a cannulated facet screw inserted over a guidewire to reduce muscle and tissue trauma.

1. 1Trans1 |trans1.com
2. 2Company | Trans1trans1.com
3. 3TranS1 (United States) - Wikidatawikidata.org